Morgan Stanley analyst James Faucette lowered the firm’s price target on Paychex (PAYX) to $148 from $150 and keeps an Equal Weight rating on the shares following what the firm calls a “slightly-soft” Q4. Paychex’s growth guidance suggests about a 5% normalized growth guide, which is “notably below investor expectations,” and the lack of organic growth guidance leaves questions around core business performance, the analyst contends.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAYX:
- Paychex price target lowered to $145 from $155 at UBS
- Paychex price target lowered to $152 from $156 at Stifel
- Sell Rating for Paychex Amid Slower Growth and Integration Challenges
- Hold Rating on Paychex Amid Acquisition Delays and Investor Skepticism
- Paychex Reports Strong Revenue Growth and Strategic Acquisition